查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128018

犬類幹細胞治療市場規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測。

Canine Stem Cell Therapy Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 124 Pages | 商品交期: 2-3個工作天內

價格

犬類幹細胞治療市場的成長要素

2025年全球犬類幹細胞治療市場規模為5,800萬美元，預計2026年將達6,700萬美元。該市場預計將顯著成長，到2034年將達到2.2億美元，在預測期（2026-2034年）內複合年成長率（CAGR）高達16.02%。這一成長主要受以下因素驅動：犬類骨關節炎、髖關節發育不良、韌帶損傷和慢性發炎性疾病的盛行率不斷上升，以及寵物飼養量的增加和對先進獸醫保健投入的增加。 2025年，北美將以41.37%的市場佔有率引領全球市場，這得益於其在寵物保健方面的強勁投入以及對再生獸醫學的早期應用。

犬類幹細胞療法包括幹細胞產品、細胞處理系統、幹細胞庫服務、專為犬類設計的治療程序。這些療法有助於減輕發炎、促進組織再生、改善運動功能，並提高患有慢性整形外科疾病和發炎性疾病的伴侶動物的生活品質。

細胞處理技術的進步正在推動市場成長。

幹細胞處理技術的進步正成為犬類幹細胞治療市場的主要趨勢。細胞分離、增殖、冷凍保存、品質控制以及符合GMP規範的生產過程的改進，顯著提高了治療的穩定性和療效。這些進步使得開發可靠的自體和異體幹細胞治療成為可能，並有望實現更大規模的商業化應用。

易於使用的幹細胞產品的日益普及縮短了治療準備時間，並提高了獸醫醫院和專科診所的治療便利性。 2025年3月，VetStem Biopharma成功資金籌措，以支持其用於治療犬骨關節炎的即用型幹細胞療法StemStat Ortho獲得美國FDA有條件批准的最後階段。

人們對再生獸醫學的認知不斷提高，從而推動了需求成長。

獸醫和寵物飼主對再生醫學的認知不斷提高，是推動市場成長的主要因素之一。幹細胞療法正日益被認為是治療犬類慢性疾病、替代傳統疼痛管理和外科手術的有效方法。

寵物飼主越來越願意投資能夠改善老年犬行動能力、舒適度和長期健康的先進療法。獸醫醫院的宣傳活動、臨床研究和行業相關人員也促進了這些療法的廣泛應用。截至2025年4月，VetStem報告在美國和加拿大實施了超過4萬例幹細胞治療，顯示人們對再生醫學的信心日益增強。

監管方面的挑戰持續阻礙擴張。

儘管該市場成長潛力巨大，但仍面臨監管方面的挑戰。各國對獸用幹細胞療法的監管力道不一，導致產品核准及商業化過程複雜化。在美國，幹細胞產品可能被視為新型動物用藥品進行監管，需要提供詳細的文件、進行安全評估並符合生產規範。

缺乏全球統一的法規會導致研發成本增加、核准時間延長、限制市場上的產品數量，並減緩市場滲透速度。

寵物醫療保健成本上漲創造了機遇

寵物醫療保健成本的不斷上漲為參與企業帶來了巨大的機會。寵物飼主越來越將狗視為家庭成員，也更願意為改善長期健康的先進療法買單。

幹細胞療法作為一種治療骨關節炎、韌帶損傷、髖關節發育不良和慢性發炎性疾病的方法，正日益受到關注。根據美國寵物用品協會預測，到2025年，美國寵物產業市場規模預計將達到1,580億美元，凸顯了支撐先進獸醫學和再生醫學解決方案的強勁經濟基礎。

高昂的醫療費用仍然是一大挑戰。

阻礙這種療法廣泛應用的主要障礙之一是其高昂的費用。幹細胞治療程序通常包括檢查、診斷、麻醉、組織採集、實驗室處理、細胞注射和後續康復，這會給飼主帶來巨大的經濟負擔。

再生醫學的保險覆蓋範圍有限，進一步推高了病患的自付費用。因此，目前這種療法主要集中在專業獸醫診所和高所得寵物飼主身上。為了促進再生醫學的普及，降低診療費用和擴大保險覆蓋範圍至關重要。

基於細分市場的分析

根據治療類型，市場可細分為自體移植、異體移植和其他。到2025年，自體移植將佔市場主導地位，這主要得益於源自犬自身脂肪組織的幹細胞日益普及。此方法可最大限度地降低免疫排斥風險，並被獸醫廣泛接受。由於易於取得的治療方法越來越多，異體移植預計將成為成長最快的領域，到2034年將以20.72%的複合年成長率成長。

按疾病分類，整形外科和肌肉骨骼疾病預計將在2025年成為市場成長的主要驅動力，並在2026年佔72.7%的市場佔有率。老年犬骨關節炎、關節痛、肌腱損傷和髖關節發育不良的高發生率持續推動市場需求。皮膚病和皮膚發炎疾病預計在預測期內將以24.44%的複合年成長率實現最高成長。

按終端用戶分類，預計獸醫院將在2025年佔市場主導地位，並在2026年佔32.3%的市場佔有率，這主要得益於其廣泛的涵蓋範圍和高效整合幹細胞治療工作流程的能力。獸醫整形外科和復健中心預計到2034年將以17.68%的複合年成長率成長。

區域趨勢

北美持續引領區域市場，預計2025年市場規模將達2,400萬美元。該地區寵物擁有率高、獸醫基礎設施先進以及再生醫學的早期應用，持續推動市場成長。預計美國市場規模將在2026年達到2,560萬美元，約佔全球銷售額的38.2%。

預計歐洲將以15.59%的複合年成長率成長，這得益於再生醫學日益普及和健全的獸醫保健體系。德國和英國仍是該地區成長要素。

預計到 2026 年，亞太地區的市場規模將達到 1,360 萬美元，這主要得益於中國、日本、澳洲、韓國和印度等國家寵物擁有率的上升、可支配收入的增加以及對高品質獸醫服務需求的成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • 犬類幹細胞治療市場的技術進步
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 主要國家和地區的監管趨勢
  • 主要國家的還款方案

第5章：2021-2034年全球犬類幹細胞治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按治療類型分類
    • 本土種植
    • 同種異體移植
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 整形外科和肌肉骨骼系統
    • 皮膚病學和皮膚炎症
    • 神經病學
    • 免疫/發炎性疾病
    • 口腔和牙齒護理
    • 眼科
    • 生殖/泌尿生殖系統
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 獸醫專科醫院
    • 動物診所
    • 獸醫整形外科及復健中心
    • 學術研究機構
    • 獸醫再生醫學中心
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美犬類幹細胞治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲犬類幹細胞治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區犬類幹細胞治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲犬類幹細胞療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲犬類幹細胞治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • VetStem, Inc.
    • EquiCord
    • Ardent Animal Health, LLC
    • Bioceltix SA
    • Gallant
    • StemcellX
    • Cell Therapy Sciences Ltd.
    • Animacel
    • Enovis（Companion Animal Health）
    • JangoPet, LLC.
Product Code: FBI116136

Growth Factors of canine stem cell therapy Market

The global canine stem cell therapy market was valued at USD 58.0 million in 2025 and is expected to reach USD 67.0 million in 2026. The market is forecast to grow substantially and attain USD 220.0 million by 2034, registering a robust CAGR of 16.02% during the forecast period (2026-2034). The increasing prevalence of osteoarthritis, hip dysplasia, ligament injuries, and chronic inflammatory conditions in dogs, coupled with growing pet ownership and rising expenditure on advanced veterinary healthcare, is fueling market expansion. In 2025, North America dominated the global market with a 41.37% share, supported by strong pet healthcare spending and early adoption of regenerative veterinary medicine.

Canine stem cell therapy involves the use of stem cell-based products, cell processing systems, banking services, and treatment procedures designed specifically for dogs. These therapies help reduce inflammation, promote tissue regeneration, improve mobility, and enhance the quality of life for companion animals suffering from chronic orthopedic and inflammatory disorders.

Advancements in Cell Processing Technologies Driving Market Growth

Technological progress in stem cell processing is emerging as a major trend within the canine stem cell therapy market. Improvements in cell isolation, expansion, cryopreservation, quality testing, and GMP-compliant manufacturing have significantly enhanced treatment consistency and effectiveness. These advancements enable the development of reliable autologous and allogeneic stem cell therapies that can be commercialized on a larger scale.

The growing availability of ready-to-use stem cell products is reducing treatment preparation times and improving accessibility for veterinary clinics and specialty hospitals. In March 2025, VetStem Biopharma secured strategic funding to support the final stages of U.S. FDA conditional approval for StemStat Ortho, an off-the-shelf stem cell therapy developed for canine osteoarthritis.

Growing Awareness of Regenerative Veterinary Medicine Boosting Demand

Increasing awareness regarding regenerative medicine among veterinarians and pet owners is one of the primary factors driving market growth. Stem cell therapy is increasingly recognized as an effective alternative to traditional pain management and surgical interventions for chronic canine conditions.

Pet owners are becoming more willing to invest in advanced therapies that improve mobility, comfort, and long-term health outcomes for aging dogs. Educational initiatives from veterinary hospitals, clinical studies, and industry participants are also contributing to wider adoption. In April 2025, VetStem reported processing more than 40,000 stem cell treatments across the U.S. and Canada, demonstrating growing confidence in regenerative therapies.

Regulatory Challenges Continue to Restrict Expansion

Despite strong growth potential, the market faces regulatory challenges. Veterinary stem cell therapies are subject to varying regulations across different countries, creating complexities for product approval and commercialization. In the U.S., stem cell products may be regulated as new animal drugs, requiring extensive documentation, safety evaluations, and manufacturing compliance.

The lack of harmonized global regulations increases development costs and extends approval timelines, limiting the number of commercially available products and slowing market penetration.

Rising Veterinary Healthcare Spending Creating Opportunities

Growing expenditure on companion animal healthcare presents significant opportunities for market participants. Pet owners increasingly view dogs as family members and are willing to spend more on advanced treatments that improve long-term wellbeing.

Stem cell therapy is gaining traction for treating osteoarthritis, ligament injuries, hip dysplasia, and chronic inflammatory disorders. According to the American Pet Products Association, the U.S. pet industry generated USD 158 billion in 2025, highlighting the strong financial foundation supporting advanced veterinary treatments and regenerative medicine solutions.

High Treatment Costs Remain a Key Challenge

One of the major barriers to broader adoption is the high cost of treatment. Stem cell therapy procedures often involve consultation, diagnostics, anesthesia, tissue harvesting, laboratory processing, cell injections, and follow-up rehabilitation, resulting in substantial expenses for pet owners.

Limited insurance reimbursement for regenerative therapies further increases out-of-pocket costs. As a result, adoption remains concentrated among specialty veterinary hospitals and higher-income pet owners. Reducing processing costs and expanding insurance coverage will be critical to supporting wider acceptance.

Segmental Analysis

Based on therapy type, the market is segmented into autologous, allogeneic, and others. The autologous segment dominated the market in 2025, driven by the widespread use of stem cells derived from a dog's own adipose tissue. This approach minimizes the risk of immune rejection and has gained strong acceptance among veterinarians. The allogeneic segment is projected to register the fastest growth, expanding at a CAGR of 20.72% through 2034 due to the increasing availability of ready-to-use therapies.

By disease indication, the orthopedic and musculoskeletal segment led the market in 2025 and is expected to account for 72.7% of market share in 2026. High prevalence of osteoarthritis, joint pain, tendon injuries, and hip dysplasia among aging dogs continues to drive demand. The dermatology and skin inflammation segment is anticipated to record the highest CAGR of 24.44% during the forecast period.

Based on end user, veterinary clinics dominated the market in 2025 and are expected to hold 32.3% market share in 2026 due to their broad accessibility and ability to coordinate stem cell therapy workflows efficiently. Veterinary orthopedic and rehabilitation centers are projected to grow at a CAGR of 17.68% through 2034.

Regional Insights

North America remained the leading regional market, reaching USD 24.0 million in 2025. Strong pet ownership rates, advanced veterinary infrastructure, and early adoption of regenerative medicine continue to support regional growth. The U.S. market is projected to reach USD 25.6 million in 2026, representing approximately 38.2% of global revenues.

Europe is expected to grow at a CAGR of 15.59%, supported by increasing acceptance of regenerative therapies and favorable veterinary healthcare systems. Germany and the U.K. remain key regional contributors.

Asia Pacific is projected to reach USD 13.6 million in 2026, driven by rising pet adoption, growing disposable income, and increasing demand for premium veterinary care in countries such as China, Japan, Australia, South Korea, and India.

Competitive Landscape

The market is moderately consolidated, with leading companies focusing on autologous stem cell processing, cell banking services, and development of ready-to-use allogeneic therapies. Key companies include VetStem, Inc., EquiCord, Ardent Animal Health LLC, Bioceltix S.A., Gallant, StemcellX, Cell Therapy Sciences Ltd., Animacel, Enovis (Companion Animal Health), and JangoPet LLC.

Recent developments include Bioceltix's large-scale manufacturing facility approval in February 2026, Gallant's USD 18 million Series B funding round in June 2025, and ongoing clinical advancements in stem cell therapies for canine osteoarthritis and atopic dermatitis.

Conclusion

The global canine stem cell therapy market is poised for substantial expansion, growing from USD 58.0 million in 2025 to USD 67.0 million in 2026, and reaching USD 220.0 million by 2034. Rising awareness of regenerative veterinary medicine, increasing pet healthcare expenditure, technological advancements in stem cell processing, and growing demand for non-surgical treatment options are expected to drive market growth. While regulatory complexities and high treatment costs remain challenges, continuous innovation and expanding clinical acceptance will support the long-term development of the canine stem cell therapy industry.

Segmentation By Therapy Type, Disease Indication, End User, and Region

By Therapy Type * Autologous

  • Allogeneic
  • Others

By Disease Indication * Orthopedic & Musculoskeletal

  • Dermatology & Skin Inflammation
  • Neurology
  • Immune & Inflammatory Disorders
  • Oral/Dental
  • Ophthalmic
  • Reproductive & Urogenital
  • Others

By End User * Veterinary Specialty Hospitals

  • Veterinary Clinics
  • Veterinary Ortho/Rehab Centers
  • Academic & Research Institutes
  • Veterinary Regenerative Medicine Centers
  • Others

By Region * North America (By Therapy Type, Disease Indication, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Therapy Type, Disease Indication, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, Disease Indication, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Type, Disease Indication, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Type, Disease Indication, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Technological Advancements in Canine Stem Cell Therapy Market
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Reimbursement Scenario, By Key Countries/Regions

5. Global Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.1.1. Autologous
    • 5.1.2. Allogeneic
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Orthopedic & Musculoskeletal
    • 5.2.2. Dermatology & Skin Inflammation
    • 5.2.3. Neurology
    • 5.2.4. Immune & Inflammatory Disorders
    • 5.2.5. Oral/Dental
    • 5.2.6. Ophthalmic
    • 5.2.7. Reproductive & Urogenital
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Veterinary Specialty Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Veterinary Ortho/Rehab Centers
    • 5.3.4. Academic & Research Institutes
    • 5.3.5. Veterinary Regenerative Medicine Centers
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.1.1. Autologous
    • 6.1.2. Allogeneic
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Orthopedic & Musculoskeletal
    • 6.2.2. Dermatology & Skin Inflammation
    • 6.2.3. Neurology
    • 6.2.4. Immune & Inflammatory Disorders
    • 6.2.5. Oral/Dental
    • 6.2.6. Ophthalmic
    • 6.2.7. Reproductive & Urogenital
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Veterinary Specialty Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Veterinary Ortho/Rehab Centers
    • 6.3.4. Academic & Research Institutes
    • 6.3.5. Veterinary Regenerative Medicine Centers
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.1.1. Autologous
    • 7.1.2. Allogeneic
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Orthopedic & Musculoskeletal
    • 7.2.2. Dermatology & Skin Inflammation
    • 7.2.3. Neurology
    • 7.2.4. Immune & Inflammatory Disorders
    • 7.2.5. Oral/Dental
    • 7.2.6. Ophthalmic
    • 7.2.7. Reproductive & Urogenital
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Veterinary Specialty Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Veterinary Ortho/Rehab Centers
    • 7.3.4. Academic & Research Institutes
    • 7.3.5. Veterinary Regenerative Medicine Centers
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.1.1. Autologous
    • 8.1.2. Allogeneic
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Orthopedic & Musculoskeletal
    • 8.2.2. Dermatology & Skin Inflammation
    • 8.2.3. Neurology
    • 8.2.4. Immune & Inflammatory Disorders
    • 8.2.5. Oral/Dental
    • 8.2.6. Ophthalmic
    • 8.2.7. Reproductive & Urogenital
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Veterinary Specialty Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Veterinary Ortho/Rehab Centers
    • 8.3.4. Academic & Research Institutes
    • 8.3.5. Veterinary Regenerative Medicine Centers
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.1.1. Autologous
    • 9.1.2. Allogeneic
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Orthopedic & Musculoskeletal
    • 9.2.2. Dermatology & Skin Inflammation
    • 9.2.3. Neurology
    • 9.2.4. Immune & Inflammatory Disorders
    • 9.2.5. Oral/Dental
    • 9.2.6. Ophthalmic
    • 9.2.7. Reproductive & Urogenital
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Veterinary Specialty Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Veterinary Ortho/Rehab Centers
    • 9.3.4. Academic & Research Institutes
    • 9.3.5. Veterinary Regenerative Medicine Centers
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Canine Stem Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.1.1. Autologous
    • 10.1.2. Allogeneic
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Orthopedic & Musculoskeletal
    • 10.2.2. Dermatology & Skin Inflammation
    • 10.2.3. Neurology
    • 10.2.4. Immune & Inflammatory Disorders
    • 10.2.5. Oral/Dental
    • 10.2.6. Ophthalmic
    • 10.2.7. Reproductive & Urogenital
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Veterinary Specialty Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Veterinary Ortho/Rehab Centers
    • 10.3.4. Academic & Research Institutes
    • 10.3.5. Veterinary Regenerative Medicine Centers
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. VetStem, Inc.
    • 11.2.2. EquiCord
    • 11.2.3. Ardent Animal Health, LLC
    • 11.2.4. Bioceltix S.A.
    • 11.2.5. Gallant
    • 11.2.6. StemcellX
    • 11.2.7. Cell Therapy Sciences Ltd.
    • 11.2.8. Animacel
    • 11.2.9. Enovis (Companion Animal Health)
    • 11.2.10. JangoPet, LLC.

List of Tables

  • Table 1: Global Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 2: Global Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 3: Global Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 4: Global Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Region, 2021-2034
  • Table 5: North America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 6: North America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 7: North America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 8: North America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, by Country, 2021-2034
  • Table 9: Europe Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 10: Europe Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 11: Europe Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 12: Europe Canine Stem Cell Therapy Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 14: Asia Pacific Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 15: Asia Pacific Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 16: Asia Pacific Canine Stem Cell Therapy Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 17: Latin America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 18: Latin America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 19: Latin America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 20: Latin America Canine Stem Cell Therapy Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Therapy Type, 2021-2034
  • Table 22: Middle East & Africa Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Canine Stem Cell Therapy Market Revenue (USD million) Forecast, By End User, 2021-2034
  • Table 24: Middle East & Africa Canine Stem Cell Therapy Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Canine Stem Cell Therapy Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
  • Figure 2: Global Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025 & 2034
  • Figure 3: Global Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025 & 2034
  • Figure 4: Global Canine Stem Cell Therapy Market Value Share (%), By End User, 2025 & 2034
  • Figure 5: Global Canine Stem Cell Therapy Market Value Share (%), By Region, 2025 & 2034
  • Figure 6: North America Canine Stem Cell Therapy Market Value (USD million), By Therapy Type, 2025 & 2034
  • Figure 7: North America Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 8: North America Canine Stem Cell Therapy Market Value (USD million), By Disease Indication, 2025 & 2034
  • Figure 9: North America Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025
  • Figure 10: North America Canine Stem Cell Therapy Market Value (USD million), By End User, 2025 & 2034
  • Figure 11: North America Canine Stem Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 12: North America Canine Stem Cell Therapy Market Value (USD million), by Country, 2025 & 2034
  • Figure 13: North America Canine Stem Cell Therapy Market Value Share (%), by Country, 2025
  • Figure 14: Europe Canine Stem Cell Therapy Market Value (USD million), By Therapy Type, 2025 & 2034
  • Figure 15: Europe Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 16: Europe Canine Stem Cell Therapy Market Value (USD million), By Disease Indication, 2025 & 2034
  • Figure 17: Europe Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025
  • Figure 18: Europe Canine Stem Cell Therapy Market Value (USD million), By End User, 2025 & 2034
  • Figure 19: Europe Canine Stem Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 20: Europe Canine Stem Cell Therapy Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Canine Stem Cell Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Canine Stem Cell Therapy Market Value (USD million), By Therapy Type, 2025 & 2034
  • Figure 23: Asia Pacific Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 24: Asia Pacific Canine Stem Cell Therapy Market Value (USD million), By Disease Indication, 2025 & 2034
  • Figure 25: Asia Pacific Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025
  • Figure 26: Asia Pacific Canine Stem Cell Therapy Market Value (USD million), By End User, 2025 & 2034
  • Figure 27: Asia Pacific Canine Stem Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 28: Asia Pacific Canine Stem Cell Therapy Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Canine Stem Cell Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Canine Stem Cell Therapy Market Value (USD million), By Therapy Type, 2025 & 2034
  • Figure 31: Latin America Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 32: Latin America Canine Stem Cell Therapy Market Value (USD million), By Disease Indication, 2025 & 2034
  • Figure 33: Latin America Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025
  • Figure 34: Latin America Canine Stem Cell Therapy Market Value (USD million), By End User, 2025 & 2034
  • Figure 35: Latin America Canine Stem Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 36: Latin America Canine Stem Cell Therapy Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Canine Stem Cell Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Canine Stem Cell Therapy Market Value (USD million), By Therapy Type, 2025 & 2034
  • Figure 39: Middle East & Africa Canine Stem Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 40: Middle East & Africa Canine Stem Cell Therapy Market Value (USD million), By Disease Indication, 2025 & 2034
  • Figure 41: Middle East & Africa Canine Stem Cell Therapy Market Value Share (%), By Disease Indication, 2025
  • Figure 42: Middle East & Africa Canine Stem Cell Therapy Market Value (USD million), By End User, 2025 & 2034
  • Figure 43: Middle East & Africa Canine Stem Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 44: Middle East & Africa Canine Stem Cell Therapy Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Canine Stem Cell Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Canine Stem Cell Therapy Market Share (%), by Company, 2025